Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

NEXT STORY
Global Veterinary Dermatology Drugs Market By Route of Administration, By Distribution Channel, By Drug Indication, By Animal Type, By Regional Outlook, Industry Analysis Report and Forecast, 2021 – 2027
PREV STORY
Surface Oncology Named a 2021 Top Place to Work by the Boston Globe
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chembio Announces Return of President and CEO John Sperzel

MEDFORD, N.Y., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in ...

author_avatar
NASDAQ Market News

Thyas Obtains Exclusive Rights to Manufacture Induced Pluripotent Stem Cells-Derived Killer T Cells for Autologous Immunotherapy

KYOTO, Japan, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Thyas Co. Ltd. (Thyas) signed a ...

author_avatar
NASDAQ Market News

Cempra Appoints Dr. David Zaccardelli to Board of Directors

CHAPEL HILL, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

author_avatar
NASDAQ Market News